
Now that the UK Prime Minister Theresa May’s request for a Brexit deadline extension has been granted, it will provide time to make needed preparations, says Paul Brooks, executive director of the Regulatory Affairs Professionals Society (RAPS).
Uncertainty about what will happen after the UK leaves the European Union has been a major concern for regulatory affairs professionals working in pharmaceutical and medical device companies since the day the result of the Brexit referendum was announced in 2016.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze